NCT02225704 2026-04-13
Radium-223 in Combination With Enzalutamide
Cancer Trials Ireland
Phase 2 Completed
Clinical Trials
26 trialsNCT06389097 2026-03-30
(SEEtoTREAT)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recruiting
NCT04206319 2026-03-16
Radium-223 in Biochemically Recurrent Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT04109729 2026-03-02
Rad2Nivo
University of Utah
Phase 1 Active not recruiting
NCT03574571 2026-02-27
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 3 Active not recruiting
NCT04704505 2026-02-06
BAT-RAD
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT05701007 2026-01-29
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Pfizer
Completed
NCT05133440 2026-01-21
A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05924672 2026-01-14
Efficacy of Ra-223 in PSMA PET Optimally Selected Patients
University of California, San Francisco
Phase 2 Active not recruiting
NCT04037358 2025-12-19
RAVENS
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03737370 2025-10-07
Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
Tufts Medical Center
Phase 1 Completed
NCT02194842 2025-09-19
PEACE III
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Active not recruiting
NCT03093428 2025-03-28
Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC
Dana-Farber Cancer Institute
Phase 2 Completed
NCT05383079 2025-02-07
AlphaBet
Peter MacCallum Cancer Centre, Australia
Phase 1/2 Active not recruiting
NCT03002220 2024-12-11
EXCAAPE
MedSIR
Phase 2 Completed
NCT03230734 2024-09-27
RAPSON
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Active not recruiting
NCT03432949 2024-01-24
TRANCE
University Health Network, Toronto
Phase 4 Unknown
NCT05771896 2023-09-14
CARE
GenesisCare USA
Phase 3 Withdrawn
NCT02278055 2023-04-07
Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03896984 2021-12-29
PHENIX
Bayer
Completed
NCT03305224 2021-09-09
CORE-OCU
Osaka City University
Phase 2 Unknown
NCT02463799 2021-07-08
Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03563014 2020-05-20
BELFIGO
Bayer
Completed
NCT02406521 2020-03-04
Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
Dana-Farber Cancer Institute
Phase 1 Completed
NCT04110782 2019-10-01
RaProRad
Azienda Policlinico Umberto I
Unknown
NCT03208712 2018-10-24
Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy
University of Michigan Rogel Cancer Center
Phase EARLY_PHASE1 Terminated